adherence, and they demonstrated that doctors were only able to correctly identify non-adherent patients in 2/3 of cases or fared no better than chance (for a review see [2 ] ). The aim of this study is to evaluate the relation between the patients' adherence to antidepressant treatment, their doctors' perception and their therapeutic alliance.
*Bath authors contributed equally to this study.
200 adult outpatients treated with antidepressants for anxiety and/or mood disorders at the Hôpital de Cery, Prilly-Lausanne, Switzerland were approached for participation in this transversal observational study. 104 patients were included, 96 patients being excluded because of language problems or because they did not agree to participate. Adherence was evaluated with an interview of the patients (by an investigator not involved in their follow-up) and antidepressant blood level measurement. The doctor conducting the interview had access to the patients' medical charts. Blood sampling took place immediately after recruiting and interviewing patients for the study, excluding thus additional drug intake. Patients were informed that the data collected during the study would not be transmitted to their treating physicians. The interview included a validated self-reported medication-taking scale [3] : "Do you ever forget to take your medicine?", "Are you careless at times about taking your medicine?", "When you feel better, do you sometimes stop taking your medicine?", "Sometimes ifyou feel worse when you take the medicine, do you stop taking it?". Affirmative answers scored one point and led to the calculation of a 0-4 point score, higher scores indicating poorer adherence [3] . In parallel, the treating doctors also evaluated their patient's adherence as a 0-4 point score (0, very good compliance; 4, poor compliance).
The interview also included questions on reasons for discontinuation of treatment and on the information received from their treating doctor on the correct time of administration and the possible side-effects of their treatment. The degree of satisfaction with antidepressant treatment was also evaluated with a 4-item questionnaire including global satisfaction, control of the symptoms and intensity of side-effects using 5-and 6-point Likert scales (psychometric scales used to specify the level of agreement to a statement). The strength of the patient-therapist alliance, which is based on the collaboration and bond between therapist and patient, was measured by the patient's and therapist's version of the Helping Alliance questionnaire (HAq-11), a widely used 19-item questionnaire with each item rated on a 6-point Likert scale [4] . Written informed consent was obtained from ail patients. The study was approved by the psychiatry ethics committee of the University of Lausanne, Switzerland. The plasma concentrations of ail the antidepressants except for nefadozone and doxepine were measured as previously described [5] [6] [7] [8] . Chi-squared test for association, Mann-Whitney U test, Kruskal-Wallis test and/or Spearman correlation were used. Ali tests were performed with STATA (11.0; StataCorp, USA), and p s 0.05 was considered as statistically significant.
The present results are based on the data of 104 patients: 55 (53%) men (43±11 years old) and 49 (47%) women (39±11 years old), mean weight of 74±16kg, 51 (50%) smokers. 88 patients (85 %) took other medication(s), among them 8 (8 %) took 2 antidepressants. The antidepressant treatments with their median daily dose are described in c The self-report of adherence yielded a score of 0 points (very good adherence) for 32 patients (31 %), 1 point for 38 patients (37%), 2 points for 23 patients (22 %) and 3 points for 11 patients (11 %). No patients had a self-estimated score of 4 points (poor adherence). The median score for ail patients was 1. The most frequent yes-answered questions were about carelessness ( 52 %) and forgetfulness ( 46 %), whereas discontinuation of treatment when feeling better ( 15 %) or worse (2 %) was Jess frequent. Selfreported adherence scores were shown to be a useful method to identify non-adherent patients as compared to the micrapracessor-based medication event monitoring system (MEMS), a system which records the precise time of opening of the tablet container [9] . Patients with mood disorders reported a better adherence compared to patients with anxiety disorders, with 82% of patients with mood disorder (n=38) reporting a score of O or 1 vs. 52 % of patients with anxiety disorder (n = 31; X 2 = 7 .1; p=0.008). The self-reported adherence scores increased with the median treatment duration, except for patients with the Iowest adherence (9 months for 0-point score, 12 months for 1-point, 23 months for 2-point and 5 months for 3-point; p=0.04). The adherence was estimated by the doctors for 99 patients. It yielded a score of 0 point for 23 patients (23 %), 1 point for 46 patients (46%), 2 points for 20 patients (20%), 3 points for 8 patients (8 %) and 4 points for 2 patients (2 %). The median adherence score estimated by the doctors was 1 point. The distribution of the adherence scores estimated by the patients and the doctors was significantly different (o Fig. la; p=0.009) even though the scores were correlated (p=0.32; p=0.0012). The 2 scores matched for 39 patients; whereas the doctors overestimated the score compared to the patients in 29 cases and underestimated it in 31 cases. This relatively poor estimation is in agreement with the few published reports on this subject (for a review see [2] ). The self-estimation of the global satisfaction with the medication indicated that 9 patients (9%) were dissatisfied to very dissatisfied, 63 patients (61 %) were satisfied to very satisfied and 32 patients (31 %) were neither satisfied nor dissatisfied. Concerning the contrai of the symptoms, 12 patients ( 12 %) reported that their medication did not help at ail, 56 patients (54%) reported a little or moderate help and 36 patients (35 %) a large or enormous help. Among the 104 patients, 48 (46%) declared having side effects, which were estimated as being very light to light (30%), moderate to average (68%) and severe (2%). The most frequent reported side-effects were Joss oflibido (n=18), tiredness ( n = 14 ), gastraintestinal prablems ( n = 12 ), sudation and hot flushes (n=10), dry mouth (n=8), weightgain (n=7) and headache (n=6). None of these estimations was related to the self-reported adherence score (p>0.3). In addition, 31 patients (30%) estimated that their doctor did not inform them sufficiently about the importance of the dose, frequency and time of administrations; whereas 60 patients (58%) estimated that they were not sufficiently informed about the possible side-effects. Bath answers were not related to the self-reported adherence score or the degree of satisfaction from treatment (p > 0.1 ). During the interview, 16 patients (15 %) declared having discontinued the antidepressant, and most ofthem (8 out of 11 answers) did not inform their doctor. Among these 16 patients, 6 (38 %) had a self-reported adherence score of 3 points, vs. 5 of 88 patients (6%) still taking their treatment (x 2 =28.4, p<0.0005). The antidepressant blood concentration was measured for 101 patients, and 7 patients (7%) had undetectable or very low plasma concentrations (in relation to the dose and the interval sin ce the Iast intake: < 10 % of the expected concentration [ 10] ), suggesting very poor or non-adherence. Their self-report of adherence was significantly different from the rest of the patients (median scores 3 and 1, respectively; p=0.02). 4 of these 7 patients (57%) had a self-reported score of3 points, vs~ 7 of the other 94 patients (7%; x 2 =16.6, p=0.001). In addition, 31 patients (30%) were considered as possibly partially non-adherent (concentration of antidepressant and/or its main metabolite inferior to 1 /3 of the expected traugh concentration for the dose [10] and/or if the patients declared having discontinued their treatment). Their self-report of adherence was also significantly different from the rest of the patients ( median scores 2 and 1, respectively; ps0.00005). 8 ofthese 31 patients (26%) had a selfreported score of 3 points, vs. 3 of the other 71 patients (4%; x2=24.7, ps0.0005). On the other hand, the adherence scores estimated by the doctors were not significantly different between patients with undetectable or very Iow plasma concentrations vs. the others, or between patients with partial adherence vs. the others (p~0.1). Thus, the self-reported adherence score is more in accordance with the information obtained with the blood concentration than the doctors' estimation of adherence. Still, the observation of partial adherence deduced from Table 1 Clinical diagnosis according to ICD-10(n=102; patients might have up to 4 diagnoses) and antidepressant treatment (n = 104) of patients. frequency and time of administration (p=0.05). On the other hand, the therapist scores were not found to be different (p > 0.1 ). Thus, the Helping Alliance score does not seem to be related to adherence but to the satisfaction and information received. It should be mentioned that this study was conducted in an academic training institution, in which therapists may change as often as once every 6 months, and this circumstance might have affected the patient-therapist alliance. Because of this specific setting, generalization of these data to other settings might not be possible. On the other hand, the frequency of change of therapists is unlikely to have contributed to a major extent to the adherence to treatment measured in the present study as a fast decline in adherence within the first 3 months of therapy has been constantly shown in several studies [1, 2] .
In conclusion, the estimations of adherence to antidepressant treatment by patients and doctors were significantly different, though slightly correlated. Neither score was related to satisfaction with the medication, contrai of the symptoms or sideeffects. A simple self-reported adherence score was shown to be an easy and useful method to identify non-adherent patients. However, because patients were informed that data collected during the study would not be transmitted to their treating physicians, the reliability of the self-reported adherence score remains to be determined in the absence of such a non-disclo-sure assurance. The strength of the patient-therapist alliance seemed more closely related to the satisfaction with the medication and the information received on medication and sideeffects than to adherence, th us highlighting the need of patient education on compliance. Finally, adherence measured by drug plasma concentration, despite being higher than expected, was in line with the patients' self-reported score but not with the doctors' estimation. Because antidepressant treatment is a Iongterm treatment and compliance a very important issue, therapeutic drug monitoring could be useful to estimate patient's compliance and/or in case of non-response [10] .
